Skip to main content
OSTEOPORE LIMITED logo

OSTEOPORE LIMITED — Investor Relations & Filings

Ticker · OSX ISIN · AU0000053324 ASX Manufacturing
Open in API
Filings indexed 488 across all filing types
Latest filing 2023-03-30 Annual Report
Country AU Australia
Listing ASX OSX

About OSTEOPORE LIMITED

https://osteopore.com

Osteopore Limited specializes in the design and manufacture of 3D-printed bioresorbable implants. The company utilizes a patented 3D printing process to create scaffolds from bioresorbable polymers, such as polycaprolactone, designed to mimic the natural microstructure of bone. These implants, including the Osteoplug, Osteomesh, and Osteostrip product lines, are applied in neurosurgical, craniofacial, and orthopedic procedures to facilitate bone healing and tissue regeneration. The scaffolds provide a temporary structural framework that supports the body's natural healing process before being gradually absorbed and replaced by the patient's own bone tissue. This technology aims to reduce long-term complications associated with permanent foreign implants by promoting natural tissue integration and restoration across various clinical applications.

Recent filings

Filing Released Lang Actions
Annual Report to Shareholders 61 pages 983.7KB
Annual Report Classification · 100% confidence The document is titled 'Consolidated Annual Report For the year ended 31 December 2022' and contains detailed sections typical of an annual report, including a letter from the chairman, directors' report, auditor's independence declaration, consolidated financial statements, notes to the financial statements, directors' declaration, and independent auditor's report. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content includes comprehensive financial data, operational review, corporate governance information, and auditor's report, all consistent with an official annual report. Therefore, the document fits the definition of an Annual Report (10-K). FY 2022
2023-03-30 English
Appendix 4G and Corporate Governance Statement 21 pages 480.2KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a form used by ASX-listed entities to confirm compliance with corporate governance disclosure requirements. The document includes a checklist of governance principles and recommendations, indicating whether the company has followed them and where disclosures can be found (e.g., in the corporate governance statement or annual report). It explicitly states that Appendix 4G is lodged with the annual report but is not a substitute for the corporate governance statement itself. The document is a regulatory filing required by the ASX to confirm governance disclosures, not the annual report or the governance statement itself. It is a compliance and disclosure verification form, typical of Regulatory Filings (RNS). The document length (15,000 characters) and detailed content confirm it is not a brief announcement or a report publication notice. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-03-30 English
Results of General Meeting 2 pages 267.0KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Results of General Meeting' and details the voting outcomes of resolutions passed at a General Meeting held on 31 March 2023. It includes specific voting results, percentages, and proxies received for each resolution. The content is focused on the official announcement of shareholder voting results rather than the meeting materials, management discussion, or financial data. The document length is 3682 characters, which is relatively short and consistent with a voting results announcement. There is no indication of full financial reports, management commentary, or presentations. Therefore, this document fits the category of 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2023-03-30 English
Non-Renounceable Entitlement Offer Extension 2 pages 164.9KB
Capital/Financing Update Classification · 100% confidence The document is an ASX release from Osteopore Limited regarding an extension of the closing date for a Non-renounceable Entitlement Offer, which is a capital raising activity. It details the timetable for the offer, including dates for lodgement of prospectus, record date, closing date extension, and quotation of securities. There is no financial report or detailed financial statements included, nor is it a report publication announcement or certification. The content clearly relates to a financing update about the company's capital raising process.
2023-03-29 English
Update - Proposed issue of securities - OSX 63 pages 797.8KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard form used by entities listed on the Australian Securities Exchange (ASX) to announce a proposed issue of securities. It includes detailed information about the entity, the type of securities issue (such as pro rata issues, placements, bonus issues), and updates to previous announcements. The document is regulatory in nature, providing information about capital raising activities and compliance with ASX listing rules. It is not a full financial report, earnings release, or management discussion, but rather a formal announcement of a capital/financing event. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is a substantive announcement, not merely a brief notice or report publication announcement.
2023-03-29 English
OSX Product Approved for Additional Applications in Taiwan 2 pages 202.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX release announcing that Osteopore Limited has secured regulatory approval in Taiwan for an additional application of its Osteomesh product. The content focuses on product approval, market expansion, and growth opportunities. There is no financial data, no mention of a report being attached or published, and no indication of a detailed financial or management report. The document is a regulatory announcement about product approval and market development, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2023-03-26 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.